Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.0869 USD
−9.99 M USD
19.05 M USD
25.99 M
About Opus Genetics, Inc.
Sector
CEO
George Magrath
Headquarters
Farmington Hills
Website
Founded
2018
FIGI
BBG000BT34Q3
Opus Genetics, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IRD is 0.9785 USD — it has decreased by −0.87% in the past 24 hours. Watch Opus Genetics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Opus Genetics, Inc. stocks are traded under the ticker IRD.
IRD stock has fallen by −14.17% compared to the previous week, the month change is a 3.00% rise, over the last year Opus Genetics, Inc. has showed a −62.79% decrease.
We've gathered analysts' opinions on Opus Genetics, Inc. future price: according to them, IRD price has a max estimate of 15.00 USD and a min estimate of 8.00 USD. Watch IRD chart and read a more detailed Opus Genetics, Inc. stock forecast: see what analysts think of Opus Genetics, Inc. and suggest that you do with its stocks.
IRD stock is 12.42% volatile and has beta coefficient of 0.54. Track Opus Genetics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Opus Genetics, Inc. there?
Today Opus Genetics, Inc. has the market capitalization of 30.89 M, it has decreased by −24.03% over the last week.
Yes, you can track Opus Genetics, Inc. financials in yearly and quarterly reports right on TradingView.
Opus Genetics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
IRD earnings for the last quarter are −0.29 USD per share, whereas the estimation was −0.24 USD resulting in a −22.11% surprise. The estimated earnings for the next quarter are −0.06 USD per share. See more details about Opus Genetics, Inc. earnings.
Opus Genetics, Inc. revenue for the last quarter amounts to 3.87 M USD, despite the estimated figure of 2.28 M USD. In the next quarter, revenue is expected to reach 8.83 M USD.
IRD net income for the last quarter is −7.53 M USD, while the quarter before that showed −7.76 M USD of net income which accounts for 3.08% change. Track more Opus Genetics, Inc. financial stats to get the full picture.
No, IRD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 14.00 employees. See our rating of the largest employees — is Opus Genetics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Opus Genetics, Inc. EBITDA is −29.47 M USD, and current EBITDA margin is −55.42%. See more stats in Opus Genetics, Inc. financial statements.
Like other stocks, IRD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Opus Genetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Opus Genetics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Opus Genetics, Inc. stock shows the sell signal. See more of Opus Genetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.